<code id='74ECA853F8'></code><style id='74ECA853F8'></style>
    • <acronym id='74ECA853F8'></acronym>
      <center id='74ECA853F8'><center id='74ECA853F8'><tfoot id='74ECA853F8'></tfoot></center><abbr id='74ECA853F8'><dir id='74ECA853F8'><tfoot id='74ECA853F8'></tfoot><noframes id='74ECA853F8'>

    • <optgroup id='74ECA853F8'><strike id='74ECA853F8'><sup id='74ECA853F8'></sup></strike><code id='74ECA853F8'></code></optgroup>
        1. <b id='74ECA853F8'><label id='74ECA853F8'><select id='74ECA853F8'><dt id='74ECA853F8'><span id='74ECA853F8'></span></dt></select></label></b><u id='74ECA853F8'></u>
          <i id='74ECA853F8'><strike id='74ECA853F8'><tt id='74ECA853F8'><pre id='74ECA853F8'></pre></tt></strike></i>

          Home / hotspot / leisure time

          leisure time


          leisure time

          author:comprehensive    Page View:8
          Franklin faces
          Adobe

          ARCH Venture Partners, one of the top investors in the biotech ecosystem, is raising $3 billion for a new fund.

          The Chicago-based firm filed paperwork with the Securities and Exchange Commission this week for what would be its 13th namesake fund. Arch estimated it would raise around $3 billion — roughly the same amount it raised during its more recent fundraising in 2022.

          advertisement

          Arch declined to comment on the new fundraising.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In